Skip to main content
. 2016 Apr 13;7(20):29306–29320. doi: 10.18632/oncotarget.8720

Figure 3. Ectopic expression of NFIB in human classical and mesenchymal GBM inhibits tumour growth.

Figure 3

(A) Both subcutaneous and intracranial xenograft tumour formation by (mesenchymal) U87 and U251 GBM cells expressing NFIB was significantly slower than vector control cells. (B) Western blot showing NFIB expression in patient-derived proneural, neural, classical and mesenchymal GBM cells lines expressing NFIB from the ubiquitin C promoter. (C) NFIB expression inhibited intracranial xenograft tumour formation by classical and mesenchymal GBM cells but not proneural or neural GBM cells.